StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
The upgrade to Buy suggests increased investor confidence, similar upgrades often lead to stock price increases.
What happened, with direct paths to the underlying reporting
HC Wainwright upgraded STTK to Buy with a $6 price forecast. Shattuck's SL-325 targets DR3 for IBD, potentially capturing market share. First healthy participants dosed in Phase 1 trial in Q3 2025. Competitors face issues with immunogenicity and durability of response. STTK stock increased 13.3% to $2.38 following the upgrade.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.